The clinically-proven TIF (Transoral Incisionless Fundoplication) procedure, performed using the innovative EsophyX surgical device from EndoGastric Solutions, is becoming a new standard in treating moderate to moderately severe GERD (gastroesophageal disease). Nearly 3,500 TIF procedures have been performed worldwide.
The procedure reconstructs a robust antireflux barrier at the gastroesophageal junction to restore it to what is believed to be its natural anatomical geometry.The procedure is based on the long-established principles of conventional GERD surgery like laparoscopic Nissen fundoplication, but it is only minutely invasive, more versatile, and free of the chronic complications (e.g., chronic dysphagia and gas bloat syndrome) commonly associated with conventional procedures. This significantly lowers the hurdle to a patient's having GERD surgery performed, and also allows for earlier intervention of the disease.
TIF also mirrors the outcomes achieved by conventional GERD procedures. There is considerable long-term clinical data showing that conventional procedures achieve effective control of reflux. Recent clinical studies show that 85% of patients are still heartburn free and 79% are still off daily PPIs at two years.1
For the first time, TIF enables surgeons to operate transorally under endoscopic guidance to create a tight, durable GE (gastroesophageal) valve while adhering to all the basic principles of conventional fundoplication surgery.
1 Cadière GB, Van Sante N, Graves JE, Gawlicka AK, Rajan A. Two-year results of a feasibility study on antireflux transoral incisionless fundoplication (TIF) using EsophyX. Surgical Endoscopy 2009; 23: 957-964.